Curated News
By: NewsRamp Editorial Staff
June 06, 2025
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients
TLDR
- Soligenix's HyBryte(TM) offers a competitive edge in treating early-stage CTCL with its FDA and EMA Orphan Drug Designation, positioning it as a leader in rare disease therapies.
- HyBryte(TM) utilizes synthetically manufactured hypericin, a highly photoactive compound, proven effective through Phase 3 trials for early-stage CTCL treatment, demonstrating a clear mechanism of action.
- HyBryte(TM) represents hope for CTCL patients, offering a novel therapy that addresses both the physical and emotional challenges of this rare and debilitating disease.
- Discover HyBryte(TM), Soligenix's innovative photodynamic therapy, transforming CTCL treatment with its unique use of hypericin, one of the most photoactive compounds known.
Impact - Why it Matters
This news is crucial for patients suffering from CTCL, a rare and painful condition with limited treatment options. HyBryte(TM)'s development and recognition by regulatory bodies signify a potential breakthrough in managing this debilitating disease, offering hope for improved quality of life and outcomes for affected individuals. The advancement of such therapies underscores the importance of continued investment and research in rare diseases.
Summary
Soligenix, a late-stage biopharmaceutical company, is making strides in the treatment of Cutaneous T-cell lymphoma (CTCL) with its innovative therapy, HyBryte(TM). This rare and debilitating form of non-Hodgkin’s lymphoma primarily affects the skin, leading to significant physical and emotional distress for patients. HyBryte(TM), a photodynamic therapy utilizing synthetically manufactured hypericin, has shown promising results in clinical trials, including a Phase 3 trial for early-stage CTCL patients. The therapy has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency, highlighting its potential to address the urgent need for effective CTCL treatments. Soligenix (NASDAQ: SNGX) is at the forefront of developing solutions for rare diseases, with HyBryte(TM) representing a beacon of hope for those affected by CTCL. For more details, Read More>>.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients
